{"entity":{"id":"avencell-therapeutics","kind":"company","name":"AvenCell Therapeutics","aka":[],"tldr":"AvenCell Therapeutics makes CAR-T cell therapies that can be switched on and off after they are given, including ready-made versions from donor cells. It is testing them in acute myeloid leukaemia and in B-cell lymphomas.","summary":"AvenCell Therapeutics, Inc. was launched in June 2021 with a $250 million commitment from Blackstone Life Sciences as sole founding investor, combining the switchable universal CAR-T technology of GEMoaB GmbH (now AvenCell Europe GmbH, Dresden) with a licence to Intellia's CRISPR/Cas9 allogeneic platform. It is headquartered in Watertown, Massachusetts. Its switchable RevCAR receptors are directed by separately dosed bridging proteins, so CAR-T activity can be turned off and on after infusion. AVC-101 (autologous) and AVC-201 (CRISPR-engineered allogeneic) target CD123 in relapsed or refractory AML. AVC-203 (Allo-QuadCAR01-T) is a CRISPR-engineered allogeneic CD19/CD20 dual-targeting switchable CAR-T; the first patient in its QUADvance study was dosed in April 2026, supported by a grant of up to $40 million from the Japan Agency for Medical Research and Development. The company raised a $112 million Series B led by Novo Holdings in October 2024. Its first trial registered on ClinicalTrials.gov under its own name, NCT07284433, the phase 1/2 QUADvance study of Allo-QuadCAR01-T in relapsed or refractory B-cell malignancies, was posted in December 2025.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://avencell.com/"},{"label":"Series B press release, October 2024","url":"https://avencell.com/avencell-raises-112-million-in-series-b-funding-led-by-novo-holdings/"},{"label":"First patient dosed with AVC-203, April 2026","url":"https://avencell.com/avencell-therapeutics-announces-first-patient-dosed-in-phase-i-quadvance-study-with-avc-203-a-novel-allogeneic-cd19-cd20-dual-targeting-car-t-investigational-therapy-for-the-treatment-of-relapsed-ref/"}],"tags":[],"related":[],"cancers":["dlbcl","non-hodgkin-lymphoma","aml"],"sections":["cell-therapy","immunotherapy"],"technologies":["car-t","allogeneic-cell-therapy","armored-car"],"targets":["cd19","cd20","cd123"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07284433"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The 2021 launch release said the company would be headquartered in Cambridge, Massachusetts; its current website gives Watertown, Massachusetts.","Earlier AVC-101 and AVC-201 trials in AML are not found under AvenCell's name on ClinicalTrials.gov in this scan; the December 2025 date is the first registry posting under the AvenCell sponsor name, not the company's first time in the clinic.","Founding year: the company launched in June 2021; no separate founding year is stated.","Company website and press releases read on 29 October 2026."],"hq":"Watertown, MA","country":"US","companyType":"cell-therapy","website":"https://avencell.com/","stage":"growth","investors":["novo-holdings","f-prime-capital"],"funding":[{"round":"Founding commitment","year":2021,"amountUsd":250000000,"source":"https://avencell.com/blackstone-life-sciences-cellex-cell-professionals-and-intellia-therapeutics-launch-new-car-t-cell-company/","note":"Committed by funds managed by Blackstone Life Sciences as sole founding investor."},{"round":"Series B","year":2024,"amountUsd":112000000,"source":"https://avencell.com/avencell-raises-112-million-in-series-b-funding-led-by-novo-holdings/","note":"Led by Novo Holdings with F-Prime Capital, Eight Roads Ventures Japan, Piper Heartland Healthcare Capital and NYBC Ventures, alongside Blackstone Life Sciences."},{"round":"Grant","year":2025,"amountUsd":40000000,"source":"https://avencell.com/news/","note":"Up to $40 million grant from the Japan Agency for Medical Research and Development (AMED), announced 30 June 2025."}]},"route":"/companies/avencell-therapeutics/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"allogeneic-cell-therapy","kind":"technology","name":"Allogeneic (off-the-shelf) cell therapy","route":"/technologies/allogeneic-cell-therapy/"},{"id":"armored-car","kind":"technology","name":"Armoured, logic-gated & next-gen CARs","route":"/technologies/armored-car/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"cd123","kind":"target","name":"CD123","route":"/targets/cd123/"},{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"},{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"}],"trial":[{"id":"nct07284433","kind":"trial","name":"Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies","route":"/trials/nct07284433/"}],"company":[{"id":"f-prime-capital","kind":"company","name":"F-Prime Capital","route":"/companies/f-prime-capital/"},{"id":"novo-holdings","kind":"company","name":"Novo Holdings","route":"/companies/novo-holdings/"}]}}